The prognostic role of the STK15 T91A polymorphism and of STK15 mRNA expression in patients with urothelial cell carcinoma

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1025-1030

  Schultz, Iman J ^a   Kiemeney, Lambertus A ^a   Roelofs, Rian ^a   Van Aarssen, Yvonne ^b   Babjuk, Marko ^c   Willems, Johannes L ^a   Malmström, Per Uno ^d   Swinkels, Dorine W ^a   Witjes, J Alfred ^a   De Kok, Jacques B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

mRNA expression; Prognosis; STK15; T91A polymorphism; Urothelial cell carcinoma

Indexed keywords

AURORA A KINASE; MESSENGER RNA;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; URINARY TRACT CARCINOMA; UROTHELIAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 34247118903     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature 396: 643-649, 1998.
2. Rieder CL, Faruki S and Khodjakov A: The centrosome in vertebrates: more than a microtubule-organizing center. Trends Cell Biol 11: 413-419, 2001.
3. Ghadimi BM, Sackett DL, Difilippantonio MJ, Schrock E, Neumann T, Jauho A, Auer G and Ried T: Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 27: 183-190, 2000.
4. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P and Doxsey SJ: Centrosome defects and genetic instability in malignant tumors. Cancer Res 58: 3974-3985, 1998.
5. Bischoff JR and Plowman GD: The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9: 454-459, 1999.
6. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20: 189-193, 1998.
7. Miyoshi Y, Iwao K, Egawa C and Noguchi S: Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92: 370-373, 2001.
8. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S and Lichter P: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64: 3103-3111, 2004.
9. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W and Czerniak B: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94: 1320-1329, 2002.
10. Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T, Watanabe G, Imamura M, Inazawa J and Shimada Y: The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 1827-1834, 2005.
11. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S and Balmain A: Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34: 403-412, 2003.
12. Miao X, Sun T, Wang Y, Zhang X, Tan W and Lin D: Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 64: 2680-2683, 2004.
13. Fraizer GC, Diaz MF, Lee IL, Grossman HB and Sen S: Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25: 1631-1639, 2004.
14. Mostofi FK, Sobin LH and Torloni H: Histologic typing of urinary bladders. In: Anonymous. International Histological Classification of Tumors. Geneva: World Health Organisation, p. 36, 1973.
15. Spiessl B, Beahrs OH, Hermanek P, Hutter RV, Scheibe O and Sobin LH: Anonymous TNM atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. 3rd ed., 2nd revision. Springer-Verlag, Berlin, pp. 274-279, 1992.
16. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems JL, Swinkels DW, Witjes JA, de Kok JB and Malmstrom PU: Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer 119: 1915-1919, 2006.
17. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW and Span PN: Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85: 154-159, 2005.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
19. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W and Balmain A: Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26: 1368-1373, 2005.
20. Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT and Herrmann FR: Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 32: 439-444, 2006.
21. Fuessel S, Kueppers B, Ning S, Kotzsch M, Kraemer K, Schmidt U, Meye A and Wirth MP: Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 171: 2471-2476, 2004.
22. Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, Jocham D, Sczakiel G, Gerdes J and Bohle A: Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer 105: 710-716, 2003.
23. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y and Maekawa T: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115: 978-985, 2005.